Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07357727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 77 → 88 locationsStart date moved earlier from Jun 16, 2026 to May 27, 2026 · Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 10 of 24 entries · 1 moreShow 4 more changesShow less
Start date moved earlier from Jun 16, 2026 to May 27, 2026
Eligibility criteria expanded, about 13 words
Secondary endpoints: details revised at 10 of 24 entries
Study description expanded, about 5 words
MinorTrial sites expanded: 70 → 73 locationsTrial sites expanded: 67 → 70 locationsv26Show 1 more changeShow less
Trial sites expanded: 67 → 70 locations
MinorStudy sites: 67 to 70v25
MinorTrial sites expanded: 57 → 67 locationsv24
MinorTrial sites expanded: 53 → 56 locationsv23
MinorTrial sites expanded: 49 → 53 locationsStart date: Jun 8, 2026 to Jun 16, 2026v22Show 1 more changeShow less
Start date: Jun 8, 2026 to Jun 16, 2026
MinorStudy sites: 49 to 53Start date: Jun 16, 2026 to Jun 8, 2026v21Show 1 more changeShow less
Start date: Jun 16, 2026 to Jun 8, 2026
MinorStudy sites: 47 to 49v20
MinorTrial sites expanded: 30 → 47 locationsv19
MinorStudy sites: 29 to 30v18
MinorTrial sites expanded: 25 → 29 locationsStart date: Jun 12, 2026 to Jun 16, 2026v17Show 1 more changeShow less
Start date: Jun 12, 2026 to Jun 16, 2026
MinorTrial sites expanded: 20 → 25 locationsStart date: May 27, 2026 to Jun 12, 2026v16Show 1 more changeShow less
Start date: May 27, 2026 to Jun 12, 2026
MinorStudy sites: 18 to 20v15
MinorTrial sites expanded: 15 → 18 locationsv14
MinorStudy sites: 13 to 15v13
MinorStudy sites: 11 to 13v12
MinorTrial sites expanded: 6 → 9 locationsv11
MinorStudy sites: 9 to 10v10
MinorStudy sites: 6 to 9Start date changed from estimate of May 15, 2026 to May 27, 2026v9Show 1 more changeShow less
Start date changed from estimate of May 15, 2026 to May 27, 2026
MinorStudy sites: 5 to 6v8
MinorStudy sites: 4 to 5v7
MinorStudy sites: 3 to 4v6
NotableStart date: Apr 15, 2026 to May 15, 2026Study sites: 1 to 3 · Completion date: Nov 28, 2030 to Dec 27, 2030v5Show 2 more changesShow less
Study sites: 1 to 3
Completion date: Nov 28, 2030 to Dec 27, 2030
NotableRecruitment openedStudy sites: 0 to 1 · Completion date: Dec 2, 2030 to Nov 28, 2030 · Start date: Apr 17, 2026 to Apr 15, 2026v4Show 3 more changesShow less
Study sites: 0 to 1
Completion date: Dec 2, 2030 to Nov 28, 2030
Start date: Apr 17, 2026 to Apr 15, 2026
MinorCompletion date: Dec 27, 2030 to Dec 2, 2030Start date: Apr 15, 2026 to Apr 17, 2026v3Show 1 more changeShow less
Start date: Apr 15, 2026 to Apr 17, 2026
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.